The Community United for Research and Education of Ocular Melanoma, or CURE OM, recently announced a new research grant in honor of Dr. David Eschelman of Thomas Jefferson University’s Department of Radiology specifically for the study of ocular melanoma.
Uveal melanoma, also known as ocular melanoma (OM), is diagnosed in about 2,000 people a year in this country. Though rare, it is the most common eye cancer in adults.
CURE OM was created by the Melanoma Research Foundation (MRF).
At a time when there was a major shortage of a specific liver-directed treatment for people with OM, Dr. Eschelman went to bat for patients as a fierce advocate, CURE OM stated in a recent newsletter.
Dr. Eschelman collaborated with Guerbet USA, Congress and the FDA to find a permanent new source for this drug. As a result of his perseverance, a new source of the therapy was approved in a very short time.
Because of his dedication to bringing life-changing treatments to people with OM, Guerbet USA created the second CURE OM research grant in his honor to aid research and inspire others to continue important work.
While the grant was created in Dr. Eschelman’s name, CURE OM will be accepting research proposals and decide on the recipient of the research award based on a peer-reviewed process. More information about the grant will be posted on the CURE OM website soon.
“The MRF extends sincere appreciation to Dr. Eschelman for his work and dedication, and to Guerbet USA for its support of the OM community,” the newsletter stated.